Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 10;30(32):3921-3.
doi: 10.1200/JCO.2012.43.0132. Epub 2012 Sep 17.

Gemtuzumab ozogamicin: time to resurrect?

Farhad Ravandi  1 , Elihu H Estey, Frederick R Appelbaum, Francesco Lo-Coco, Charles A Schiffer, Richard A Larson, Alan K Burnett, Hagop M Kantarjian
Affiliations

Gemtuzumab ozogamicin: time to resurrect?

Farhad Ravandi et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Bross PF, Beitz J, Chen G, et al. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490–1496. - PubMed
    1. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244–3254. - PubMed
    1. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442–1452. - PubMed
    1. Rajvanshi P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310–2314. - PubMed
    1. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578–1582. - PubMed

MeSH terms